Polymorphisms in the most oncolytic reovirus strain confer enhanced cell attachment, transcription and single-step replication kinetics.
Reovirus serotype 3 Dearing (T3D) replicates preferentially in transformed cells and is in clinical trials as a cancer therapy. Laboratory strain of T3D, however, exhibit differences in plaque size on cancer cells and differences in oncolytic activity in vivo This study aimed to determine why the most-oncolytic T3DPL lab strain of reovirus replicates more efficiently in cancer cells than other commonly used laboratory strains, T3DKC and T3DTD In single step growth curves, T3DPL titers increased at faster rates and produced ∼9-fold higher burst size. Furthermore, the number of reovirus antigen-positive cells increased more rapidly for T3DPL than T3DTD In conclusion, the most-oncolytic T3DPL possesses replication advantages in a single round of infection. Two specific mechanisms for enhanced infection by T3DPL were identified. First, T3DPL exhibited higher cell attachment, which was attributed to a higher proportion of virus particles with insufficient (≤3) σ1 cell attachment proteins. Second, T3DPL transcribed RNA at superior rates to the less-oncolytic T3D strains, attributed to polymorphisms in M1-encoding μ2 protein, as confirmed in an in vitro transcription assay, demonstrating that T3DPL has an inherent transcription advantage that is cell-independent. Accordingly, T3DPL established rapid onset of viral RNA and protein synthesis, leading to more rapid kinetics of progeny virus production, larger virus burst size, and higher levels of cell death. Together, these results emphasize the importance of paying close attention to genomic divergence between virus laboratory strains, and mechanistically, reveal the importance of rapid onset of infection for reovirus oncolysis.Importance: Reovirus serotype 3 Dearing (T3D) is in clinical trials for cancer therapy. Recently it was discovered that highly related laboratory strains of T3D exhibit large differences in their ability to replicate in cancer cells in vitro, which correlates with oncolytic activity in a murine model of melanoma. The current study reveals two mechanisms for the enhanced efficiency of T3DPL in cancer cells. Due to polymorphisms in two viral genes, within the first round of reovirus infection, T3DPL binds to cells more efficiency and more-rapidly produces viral RNAs; this increased rate of infection relative to the less-oncolytic strains gives T3DPL a strong inherent advantage that culminates in higher virus production, more cell death, and higher virus spread.